Factors associated with comorbidity development in atopic dermatitis: a cross-section study

Archives of Dermatological Research, Год журнала: 2024, Номер 317(1)

Опубликована: Ноя. 30, 2024

Identifying the characteristics of atopic dermatitis (AD) patients with its comorbidity has become increasingly crucial. We aimed to investigate relevant factors associated comorbidities in adults AD. analyzed cross-sectional data through univariate and multivariate regression analyses, encompassing 439 adult cases AD from Clinical Research Homogenization Diagnosis Treatment Project for Type 2 Inflammatory Dermatosis. It was found that 231 developed at least one comorbidity. 161 had a positive family history atopy, 292 exhibited elevated IgE levels. A allergic rhinitis or sinusitis be concurrent diseases (OR (95% CI): 2.92 (1.41–6.06) model 1; 2.71 (1.27–5.77) 2; 3.59 (1.75–7.37) 3; 3.38 (1.62–7.05) 4; 3.60 (1.83–7.08) 5; 3.56 (1.78–7.12) 6). The linkage between levels different classifications negative 0.51 (0.33–0.79) (0.33–0.80) 0.52 (0.33–0.81) 0.45 (0.29–0.71) 0.47 (0.30–0.73) Scores familial atopy 1.56 (1.00-2.44) 1.59 (1.03–2.48) 1.84 (1.19–2.84) 6) were positively comorbidities. Factors development included sinusitis, scores indicating atopy. These might contribute improved discrimination early intervention individuals

Язык: Английский

---

Genomic, Epigenomic, Transcriptomic, Proteomic and Metabolomic Approaches in Atopic Dermatitis

Current Issues in Molecular Biology, Год журнала: 2023, Номер 45(6), С. 5215 - 5231

Опубликована: Июнь 20, 2023

Atopic dermatitis (AD) is a chronic inflammatory skin disease with high prevalence in the developed countries. It associated atopic and non-atopic diseases, its close correlation comorbidities has been genetically demonstrated. One of main roles genetic studies to comprehend defects cutaneous barrier due filaggrin deficit epidermal spongiosis. Recently, epigenetic started analyze influence environmental factors on gene expression. The epigenome considered be superior second code that controls genome, which includes alterations chromatin. changes do not alter code, however, chromatin structure could activate or inhibit transcription process certain genes consequently, translation new mRNA into polypeptide chain. In-depth analysis transcriptomic, metabolomic proteomic allow unravel detailed mechanisms cause AD. extracellular space lipid metabolism are AD independent On other hand, around 45 proteins as principal components skin. Moreover, based disrupted can lead development treatments targeting inflammation. Unfortunately, at present, there no target therapies focus However, future, miR-143 an important objective for therapies, it targets miR-335:SOX axis, thereby restoring miR-335 expression, repairing defects.

Язык: Английский

---

Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib

Immunotherapy, Год журнала: 2023, Номер 15(18), С. 1521 - 1529

Опубликована: Окт. 18, 2023

Baricitinib is a JAK1-2 inhibitor recently approved in Europe and Japan for the treatment of moderate-to-severe atopic dermatitis adult patients at doses 2 4 mg daily. The aim this article to discuss safety profile baricitinib using data from clinical trials supporting literature, with focus on infectious adverse events. An integrated analysis eight described infections as most frequent treatment-emergent events, mainly mild-to-moderate severity, notably upper respiratory tract herpes simplex exacerbations. Real-world are still limited will contribute precisely that might benefit treatment.Baricitinib drug taken by mouth, currently adults who candidates systemic therapy, medication designed be absorbed into bloodstream work throughout body. available 2- 4-mg tablets has been shown improve cutaneous manifestations, such dry cracked skin, redness symptoms dermatitis, especially itchiness. generally well tolerated. common events have emerged include headache, nausea high cholesterol. Another reported side effect an increased risk infections, nasopharyngitis (inflammation nose throat) reactivation zoster, virus causes painful rash one body, simplex, which clustered blisters usually lips or genitals. There lack real-world experience, important development more precise may treatment.

Язык: Английский

---

How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(8), С. 7557 - 7557

Опубликована: Апрель 20, 2023

Atopic dermatitis (AD) is a heterogeneous disease in terms of its phenotypical, barrier, and immunological presentation. Emerging therapies are undoubtedly contributing to new chapter the treatment AD, bringing an excellent possibility individualization, thereby creating tailored approach. The two most promising substance groups biological drugs (dupilumab, tralokinumab, lebrikizumab, nemolizumab) Janus kinase inhibitors (JAKis) (baricitinib, upadacitinib, abrocitinib). vision that certain well-defined phenotypes endotypes, as well personal preferences, may guide future AD both tempting appealing, but not yet reality. accessibility such biologics small molecules has opened up discussion regarding personalized medicine, referring complex nature experiences from clinical trials real-world evidence. We have now reached point strategies goals by increasing amount information concerning efficacy safety drugs. This article reviewed novel options for light heterogeneity this proposes broader on strategy AD.

Язык: Английский

---

Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects

International Journal of Dermatology, Год журнала: 2023, Номер 63(1), С. 105 - 107

Опубликована: Ноя. 28, 2023

The data that support the findings of this study are available in PubMed: https://pubmed.ncbi.nlm.nih.gov/37098171/; https://pubmed.ncbi.nlm.nih.gov/37012527/; https://pubmed.ncbi.nlm.nih.gov/35980214/; https://pubmed.ncbi.nlm.nih.gov/36702810/; https://pubmed.ncbi.nlm.nih.gov/36660960/; https://pubmed.ncbi.nlm.nih.gov/36924265/; https://pubmed.ncbi.nlm.nih.gov/37017620/; https://pubmed.ncbi.nlm.nih.gov/37016961/; https://pubmed.ncbi.nlm.nih.gov/36404138/; https://pubmed.ncbi.nlm.nih.gov/37150301/; https://pubmed.ncbi.nlm.nih.gov/36794894/; https://pubmed.ncbi.nlm.nih.gov/36695072/.

Язык: Английский

---